ALLMedicine Hypertrophic Cardiomyopathy Center

Jun 4th, 2020 - Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by unexplained left ventricular (LV) hypertrophy associated with dynamic LV outflow tract obstruction. Current medical therapies are nonspecific and have limited efficacy in relieving...

Jun 3rd, 2020 - Specific activating missense HRAS variants cause Costello syndrome (CS), a RASopathy with recognizable facial features. The majority of these dominant disease causing variants affect the glycine residues in position 12 or 13. A clinically suspecte...

Jun 1st, 2020 - The pattern of myocardial fibrosis differs significantly between different cardiomyopathies. Fibrosis in hypertrophic cardiomyopathy (HCM) is characteristically as patchy and regional but in dilated cardiomyopathy (DCM) as diffuse and global. We s...

Jun 1st, 2020 - Invasive Hemodynamics of Hypertrophic Cardiomyopathy: Exercise Versus Isoproterenol.|2020|Caravita S,Baratto C,Perego GB,Cecchi F,Crotti L,|

May 31st, 2020 - Hypertrophic cardiomyopathy (HCM) is a prevalent cardiomyopathy in children, with variable etiologies, phenotypes, and associated syndromic genetic disorders (GD). The spectrum of evaluation in this heterogeneous population has not been well descr...

May 21st, 2019 - Question Is it possible to identify most patients with hypertrophic cardiomyopathy (HCM) at risk of arrhythmic sudden cardiac death (SCD) and to prevent such events with prophylactic implantable cardioverter/defibrillators (ICDs)? Findings In t...

Feb 4th, 2016 - Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JCS 2012)　- Digest Version .|2016| ,|diagnosis,physiopathology,therapy,

Aug 31st, 2014 - 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).|2014| ,Elliott PM,Anastasakis A,Borger MA,B...

Nov 18th, 2011 - 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.|2011| , , , , ,|diag...

Nov 14th, 2011 - 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the Ame...

Jun 4th, 2020 - Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by unexplained left ventricular (LV) hypertrophy associated with dynamic LV outflow tract obstruction. Current medical therapies are nonspecific and have limited efficacy in relieving...

Jun 3rd, 2020 - Specific activating missense HRAS variants cause Costello syndrome (CS), a RASopathy with recognizable facial features. The majority of these dominant disease causing variants affect the glycine residues in position 12 or 13. A clinically suspecte...

Jun 1st, 2020 - The pattern of myocardial fibrosis differs significantly between different cardiomyopathies. Fibrosis in hypertrophic cardiomyopathy (HCM) is characteristically as patchy and regional but in dilated cardiomyopathy (DCM) as diffuse and global. We s...

Jun 1st, 2020 - Invasive Hemodynamics of Hypertrophic Cardiomyopathy: Exercise Versus Isoproterenol.|2020|Caravita S,Baratto C,Perego GB,Cecchi F,Crotti L,|

May 31st, 2020 - Hypertrophic cardiomyopathy (HCM) is a prevalent cardiomyopathy in children, with variable etiologies, phenotypes, and associated syndromic genetic disorders (GD). The spectrum of evaluation in this heterogeneous population has not been well descr...

May 25th, 2020 - An investigational, first-in-class agent showed hypothesis-generating promise in symptomatic adults with nonobstructive hypertrophic cardiomyopathy (HCM), a condition lacking in good treatment options, in an early dose-finding study. The 40 patien...

May 21st, 2020 - Hypertrophic cardiomyopathy (HCM) is the most common inherited monogenic cardiac disorder, affecting 0.2-0.5% of the population.[1,2] In the United States, 750,000 people are estimated to have HCM; however, only approximately 100,000 people have b...

May 11th, 2020 - Patients with obstructive hypertrophic cardiomyopathy (HCM) who took an investigational agent that targets cardiac myosin over about 7 months showed across-the-board improvements in functional capacity, symptoms, and left ventricular outflow obstr...

Oct 31st, 2019 - The risk for sudden cardiac death (SCD) in adolescents and young adults with hypertrophic cardiomyopathy (HCM) is "an order of magnitude lower" than most recent estimates would indicate, a report based on comprehensive autopsy data suggests. The a...

Aug 26th, 2019 - NEW YORK (Reuters Health) - Researchers have developed a new model to predict the individualized risk of sudden cardiac death (SCD) in children with hypertrophic cardiomyopathy. Although the risk of SCD in this population is higher than that in ad...